Department Research Topics
Skin Cancer Research
Research in skin cancer has led to the identification of a substance that suppresses the development of chemical and ultraviolet induced skin cancers in animal models. This new drug shows promise in the prevention of skin cancers, as well as age-related skin changes.
Our clinical trials in psoriasis have demonstrated that ultraviolet light can be blocked by many psoriasis treatments applied to the skin and, in reverse, that some topical therapies are inactivated by ultraviolet light. Combinations of topical therapies that are incompatible have also been identified. We have a state-of-the-art Infusion Center where patients receive treatment with the new biologic therapies recently developed for psoriasis and blistering diseases such as pemphigus.
Our research staff is studying 500 patients with pseudoxanthoma elasticum, a condition that is a model for accelerated aging characterized by prematurely aged skin, eye disease, and accelerated heart disease. An abnormal fetal protein responsible for the condition has been identified. Of even greater importance, a model in which adult fibroblasts can dedifferentiate to produce a fetal protein has been developed that may enable diagnosis of pseudoxanthoma elasticum.
Members of our staff have contributed greatly to the pathogenesis and treatment of scleroderma.
New Dermatologic Drugs
We have worked on the development of many new dermatologic drugs for conditions such as psoriasis, skin cancer, mycosis fungoides, herpes, acne, onychomycosis, alopecia, eczema, and others.